{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "E",
          "alt": "G",
          "position": "344"
        },
        "variant_string_id": "PARK2 E344G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The study discusses PARK2 as a tumor suppressor gene that is inactivated and mutated in GBM, colon cancer, and lung cancer. PARK2 mutations decrease PARK2's E3 ligase activity, compromising its ability to ubiquitinate cyclin E and resulting in mitotic instability.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as the loss of PARK2's E3 ligase activity and its effect on cyclin E ubiquitination, which is central to tumor suppression."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses assays to measure the ubiquitination function of PARK2 mutants in cells, which is a well-established method to evaluate the functional impact of mutations on E3 ligase activity.",
          "judgment": "Yes",
          "reasoning": "The ubiquitination assay is a standard method used in the field to assess the functional impact of mutations on E3 ligases, making it applicable to the disease mechanism defined."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper describes the use of well-established assays to measure the ubiquitination function of PARK2 mutants in cells, which are valid for evaluating the functional impact of the E344G mutation."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "judgment": "Yes",
          "reasoning": "The paper provides evidence that the E344G mutation compromises the association of PARK2 with ubiquitinated target proteins in cancer cells, suggesting a loss of function.",
          "next_step_or_outcome": "Proceed to determine the strength of evidence."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The E344G mutation in PARK2 was found to compromise the protein's ability to associate with ubiquitinated target proteins, supporting the pathogenicity of this variant. This conclusion is based on the functional evidence that the mutation affects the E3 ligase activity of PARK2, a key function in tumor suppression."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "Q",
          "position": "275"
        },
        "variant_string_id": "PARK2 R275Q"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The study discusses PARK2 as a tumor suppressor gene that is inactivated and mutated in GBM, colon cancer, and lung cancer. PARK2 mutations decrease PARK2's E3 ligase activity, compromising its ability to ubiquitinate cyclin E and resulting in mitotic instability.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as the loss of PARK2's E3 ligase activity and its effect on cyclin E ubiquitination, which is central to tumor suppression."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The paper uses assays to measure the ubiquitination function of PARK2 mutants in cells, which is a well-established method to evaluate the functional impact of mutations on E3 ligase activity.",
          "judgment": "Yes",
          "reasoning": "The ubiquitination assay is a standard method used in the field to assess the functional impact of mutations on E3 ligases, making it applicable to the disease mechanism defined."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper describes the use of well-established assays to measure the ubiquitination function of PARK2 mutants in cells, which are valid for evaluating the functional impact of the R275Q mutation."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "judgment": "Yes",
          "reasoning": "The paper provides evidence that the R275Q mutation affects the ability of PARK2 to interact with cyclin E and compromise its ubiquitination activity, suggesting a loss of function.",
          "next_step_or_outcome": "Proceed to determine the strength of evidence."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R275Q mutation in PARK2 was found to affect the protein's ability to interact with and ubiquitinate cyclin E, supporting the pathogenicity of this variant. This conclusion is based on the functional evidence that the mutation impacts a key function of PARK2 in tumor suppression."
    }
  ]
}